CJE Maternity 1 Practice Exam

Labetalol is recognized as an approved first-line antihypertensive for use during pregnancy due to its safety profile and effectiveness in managing hypertension. It is a combined alpha and beta-adrenergic blocker, which helps reduce blood pressure without significantly impacting blood flow to the placenta, making it a preferable option for pregnant patients.

It’s essential to prioritize medications that are deemed safe for both the mother and the developing fetus, especially during pregnancy. Labetalol has been studied extensively in pregnant populations and has established guidelines supporting its use. This makes it a go-to choice for health care providers when treating conditions such as gestational hypertension and preeclampsia.

In contrast, other medications have different safety profiles during pregnancy. For instance, losartan is classified as an angiotensin receptor blocker, which is typically contraindicated because it can adversely affect fetal development. Amlodipine, a calcium channel blocker, is used for hypertension but is not considered first-line due to insufficient evidence regarding its safety during pregnancy. Diltiazem, another calcium channel blocker, may be used cautiously but again is not among the first recommendations.

Ultimately, the choice of labetalol resonates with the guidelines and research advocating for its effectiveness and safety